The final results of the APLICOV-PC study (Phase I-II), which were initially released last May and which the Company shared with the scientific community, demonstrate the safety of plitidepsin's use in patients with COVID-19 and postulate a positive therapeutic impact on the evolution of the disease.
According to the final data published in this article, plitidepsin has been shown to have a potent antiviral activity in all variants at very low (nanomolar) concentrations, with a positive in vitro therapeutic index. These studies were led by Dr.
Laboratory in vivo studies have also demonstrated a preferential distribution of plitidepsin to lung tissue, which is the organ primarily affected in patients with COVID-19. These studies showed a reduction in viral replication, resulting in a 99% decrease in viral loads in the lung of plitidepsin-treated animals.
The article also reviews data from the APLICOV-PC clinical trial, which demonstrated the safety of plitidepsin in patients with COVID-19 requiring hospital admission. The trial met the primary safety endpoint and showed clinical efficacy; in addition the study gathered consistent evidence of a plitidepsin mediated impact on viral load, on inflammatory pathways and on lymphopenia normalization.
In this Phase I-II study, 45 patients were enrolled, of whom 86.7% had moderate or severe disease. 41 patients (91%) had pneumonia, 32 (71% of the global sample) of them with bilateral pneumonia. Of note were the data observed in 23 patients with moderate disease, 74% of whom were discharged from hospital within the first week of treatment.
These results are the basis for the Phase III NEPTUNO clinical trial that is currently recruiting patients in 17 hospitals in
'It is noteworthy that the clinical data are consistent with the preclinical data, suggesting a benefit of plitidepsin administration to patients with COVID-19, and that, in pre-clinical models, plitidepsin has potent antiviral activity, not only for SARS-CoV-2 and its variants, including Delta and Omicron, but also against other coronaviruses.'
Contact:
Office
Avda. De los Reyes, 1
28770 - Colmenar Viejo,
Phone: +34 91 846 6000
Fax: 91 846 6001
(C) 2022 Electronic News Publishing, source